Wellthy Therapeutics, a Digital Therapeutics company based out of Mumbai, is one of the five companies selected, and the only Healthcare company to enrol into Swiss Re InsurTech Accelerator programme this year. Wellthy’s artificial intelligence powered mobile intervention focuses on reversing and controlling diabetes through integrated care. Wellthy facilitates behavioural change and enables on demand care to improve health through a clinically proven policyholder centric tool, while reducing risk for health and life insurers.
Indians are getting diabetes at a younger age, and complications are arising faster. More importantly, diabetics are largely ineligible for insurance. When eligible, that insurance comes at a very high premium. Insurers on the other hand find it difficult to insure diabetics, especially when the average diabetic’s blood sugar remains uncontrolled, and is at high risk of complications such as heart diseases. While the number of diabetics over the last 20 years having tripled to over 70m, alongside an estimated 80m prediabetics, the state of diabetes in India is only getting worse. With an estimated 100m diabetics in India by 2025, access to affordable insurance and clinically proven tools to control and reverse the condition, is the need of the hour.
Related Coverage
- American Diabetes Association Urges Senators to Vote Against Proposed Health Care Legislation
- Peer-Reviewed Journal Spotlights Lirio’s Approach to Behavioral Design and Its Ability to Impact Underserved Communities
For more reporting on this topic, see our Public Health and Research news hub.